Nina Greilert

Nina Greilert

Forskningssköterska
E-postadress: nina.greilert@ki.se
Telefon: +46852482610
Mobile phone: +46736251466
Besöksadress: Entrévägen 2, 18257 Danderyd
Postadress: D1 Kliniska vetenskaper, Danderyds sjukhus, D1 Administration, 182 88 Stockholm

Om mig

  • * Projetledare för COMMUNITY-studien [1]
    * Medarbetare i KFC-support, ett lokalt forskarstöd i samarbete mellan
    Karolinska Institutet och Danderyds Sjukhus
    * Koordinator för avtal som avser klinisk forskning Karolinska Institutet
    Danderyds Sjukhus
    * Andministratör för studier registrerade
    i https://www.clinicaltrials.gov/ [2] där Danderyds Sjukhus är
    forskningshuvudman
    *Publikationer:*
    Mucosal immune responses following a fourth SARS-CoV-2 vaccine dose. [3]
    Bladh O, Marking U, Havervall S, Norin NG, Aguilera K, Hober S,
    Smed-Sörensen A, Gordon M, Blom K, Åberg M, Klingström J, Thålin C
    /Lancet Microbe 2023 Apr
  • ():/
    7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and
    protection. [4]
    Marking U, Bladh O, Havervall S, Svensson J, Greilert-Norin N, Aguilera K,
    Kihlgren M, Salomonsson AC, Månsson M, Gallini R, Kriegholm C, Bacchus P,
    Hober S, Gordon M, Blom K, Smed-Sörensen A, Åberg M, Klingström J, Thålin
    C
    /Lancet Infect Dis 2023 Jan
  • ():/
    Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection [5],
    Sebastian Havervall, Ulrika Marking, Julia Svensson, Nina Greilert Norin,
    Philip Bacchus, Peter Nilsson, Sophia Hober, Max Gordon, Kim Blom, Jonas
    Klingström, Mikael Åberg, Anna Smed-Sörensen, Charlotte Thålin. /The New
    England Journal of Medicine (NEJM), Letter to the Editor, online 14 september
    2022, doi: 10.1056/NEJMc2209651/
    Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June
    2022. [6] Blom K, Havervall S, Marking U, Norin NG, Bacchus P, Groenheit R,
    Bråve A, Thålin C, Klingström J /Emerg Infect Dis 2022 Aug
  • 28(10):/
    Immune responses after omicron infection in triple-vaccinated health-care
    workers with and without previous SARS-CoV-2 infection. [7] Blom K, Marking
    U, Havervall S, Norin NG, Gordon M, García M, Tecleab T, Christ W, Forsell
    M, Phillipson M, Nilsson P, Mangsbo S, Hober S, Åberg M, Klingström J,
    Thålin C /Lancet Infect Dis 2022 07
  • 22(7):943-945/
    Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous
    or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA
    Vaccines. [8] Marking U, Havervall S, Greilert-Norin N, Ng H, Blom K,
    Nilsson P, Phillipson M, Hober S, Nilsson C, Mangsbo S, Christ W, Klingström
    J, Gordon M, Åberg M, Thålin C /Vaccines (Basel) 2022 Feb
  • 10(3):/
    Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.
    [9] Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W,
    Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M,
    Thålin C /Clin Transl Immunology 2022
  • 11(4):e1388/
    Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in
    healthcare workers previously infected with SARS-CoV-2. [10] Havervall S,
    Marking U, Greilert-Norin N, Ng H, Gordon M, Salomonsson AC, Hellström C,
    Pin E, Blom K, Mangsbo S, Phillipson M, Klingström J, Hober S, Nilsson P,
    Åberg M, Thålin C /EBioMedicine 2021 Aug
  • 70():103523/
    Robust humoral and cellular immune responses and low risk for reinfection at
    least 8 months following asymptomatic to mild COVID-19. [11] Havervall S, Ng
    H, Jernbom Falk A, Greilert-Norin N, Månberg A, Marking U, Laurén I,
    Gabrielsson L, Salomonsson AC, Aguilera K, Kihlgren M, Månsson M, Rosell A,
    Hellström C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Lord M,
    Åberg M, Hedhammar M, Tegel H, Dönnes P, Phillipson M, Nilsson P,
    Klingström J, Mangsbo S, Hober S, Thålin C /J Intern Med 2022
    01
  • 291(1):72-80/
    SARS-CoV-2 induces a durable and antigen specific humoral immunity after
    asymptomatic to mild COVID-19 infection. [12] Havervall S, Jernbom Falk A,
    Klingström J, Ng H, Greilert-Norin N, Gabrielsson L, Salomonsson AC,
    Isaksson E, Rudberg AS, Hellström C, Andersson E, Olofsson J, Skoglund L,
    Yousef J, Pin E, Christ W, Olausson M, Hedhammar M, Tegel H, Mangsbo S,
    Phillipson M, Månberg A, Hober S, Nilsson P, Thålin C /PLoS One 2022
  • 17(1):e0262169/
    Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses
    correlate with humoral responses, disease severity, and symptomatology.
    [13] Laurén I, Havervall S, Ng H, Lord M, Pettke A, Greilert-Norin N,
    Gabrielsson L, Chourlia A, Amoêdo-Leite C, Josyula VS, Eltahir M, Kerzeli I,
    Falk AJ, Hober J, Christ W, Wiberg A, Hedhammar M, Tegel H, Burman J, Xu F,
    Pin E, Månberg A, Klingström J, Christoffersson G, Hober S, Nilsson P,
    Philipson M, Dönnes P, Lindsay R, Thålin C, Mangsbo S /Immun Inflamm Dis
    2022 04
  • 10(4):e595/
    Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results
    From EFFECTS, a Randomized Controlled Trial [14]
    Lundström E, Isaksson E, Greilert Norin N, Näsman P, Wester P, Mårtensson
    B, Norrving B, Wallén H, Borg J, Hankey Gj, Hackett Ml, Mead Ge, Dennis Ms,
    Sunnerhagen Ks
    Stroke 2021
  • 52(10):3082-3087
    [1] https://ki.se/kids/medicin-vid-ki-ds
    [2] https://www.clinicaltrials.gov/
    [3] https://pubmed.ncbi.nlm.nih.gov/37086736
    [4] https://pubmed.ncbi.nlm.nih.gov/36640796
    [5] https://www.nejm.org/doi/10.1056/NEJMc2209651
    [6] https://ki.se/en/kids/35997692
    [7] https://ki.se/en/kids/35691303
    [8] https://ki.se/en/kids/35334989
    [9] https://ki.se/en/kids/35444806
    [10] https://ki.se/en/kids/34391088
    [11] https://ki.se/en/kids/34459525
    [12] https://ki.se/en/kids/35020778
    [13] https://ki.se/en/kids/35349756
    [14] http://www.ncbi.nlm.nih.gov/pubmed/34465201

Nyheter från KI

Kalenderhändelser från KI